Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Merck Announced Five-Year Data for KEYTRUDA Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer

By Charles Gross
September 11, 11:33 AM
Five-year overall survival rate of 19.4% and 18.4% for KEYTRUDA plus chemotherapy in KEYNOTE-189 and KEYNOTE-407, respectively In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials

MRK

Read More
3 minute read

AstraZeneca Announced TAGRISSO (osimertinib) Demonstrated 5.5-year Median Disease-free Survival in the Adjuvant Treatment of Patients with EGFR-mutated Lung Cancer; Data Presented at ESMO 2022

By Charles Gross
September 11, 11:29 AM
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years

AZN

Read More
5 minute read

Clovis Oncology Announced Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups; Data Presented at ESMO 2022

By Charles Gross
September 11, 11:13 AM
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO).

CLVS

Read More
3 minute read

AstraZeneca Announced Imfinzi and Tremelimumab With Chemotherapy Demonstrated Sustained Survival Benefit in Metastatic Non-small Cell Lung Cancer, Nearly Doubling the Number of Patients Alive After Three Years vs Chemotherapy

By Charles Gross
September 11, 8:39 AM
Exploratory analysis from POSEIDON Phase III trial also showed trends for overall survival benefit with a limited course of tremelimumab added to Imfinzi and chemotherapy in subgroups with high unmet need

AZN

Read More
2 minute read

Puma Biotechnology Announced Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

By Charles Gross
September 11, 7:58 AM
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant, metastatic cervical cancer at the 2022 European Society for Medical Oncology (ESMO) Congress, currently taking place in Paris, France.

PBYI

Read More
2 minute read

2 Cash Cows In The Communications Sector Providing Promising Dividends And Consistent Revenues

By Robert Kuczmarski
September 10, 10:30 AM
Since October 2021, the communications sector has been lagging behind the S&P 500, and is down 36% year-to-date. As consumer discretionary spending is decreasing due to inflationary pressures, phone and internet services will likely continue to generate revenue as internet connectivity remains a priority for most people.

CMCSA